It was in the early 1990s that BIOPHARM established itself as one of the leading companies in the fight against poultry coccidia.

Coccidiosis is a serious disease that is reported to currently still have a large global impact on the poultry industry, of around 300 million US dollars annually.

The company developed two types of live, attenuated coccidiosis vaccines for chickens, namely for breeders/layers and broilers.

LIVACOX® vaccines can be easily administered to young chicks either via drinking water or via coarsespray, with a one-time vaccination.

The vaccines are a model choice for use in poultry systems since they provide life-long immunity, displace wild oocysts, are residue-free and eco-friendly products. The number of vaccinated breeders, broilers and layers is continuously growing worldwide.

From BIOPHARM’s experience in more than 45 countries and over 20 years of LIVACOX® use in Europe, Africa, Asia, and Latin America, it is evident that despite the various environments and challenges faced in the poultry industry, the vaccines have proven their worth as a positive and valuable choice in coccidiosis management.

In a time when there is a conscious world movement towards a high level of food safety, and in which there is a growing drive for drug-free food production, the importance of attenuated vaccines is even more noteworthy as part of a working strategy in managing coccidiosis in poultry.